Asiago
Vincent Asiago, Johnston, IA US
Patent application number | Description | Published |
---|---|---|
20110123976 | Biomarkers and identification methods for the early detection and recurrence prediction of breast cancer using NMR - A method is provided for the parallel identification of one or more metabolite species within a biological sample. The method comprises analyzing the sample to produce a spectrum containing individual spectral peaks representative of the one or more metabolite species contained within the sample; subjecting each of the individual spectral peaks to a statistical pattern recognition analysis to identify the one or more metabolite species contained within the sample; and identifying the one or more metabolite species contained within the sample by analyzing the individual spectral peaks of the spectra. | 05-26-2011 |
Vincent M. Asiago, Johnston, IA US
Patent application number | Description | Published |
---|---|---|
20150056605 | IDENTIFICATION OF BLOOD BASED METABOLITE BIOMARKERS OF PANCREATIC CANCER - The present disclosure relates to a panel of a plurality of metabolite species that is useful for the identification or detection of subjects having pancreatic cancer, including methods for identifying such metabolic biomarkers within biological samples. The disclosure also includes a statistical model for predicting the presence of pancreatic cancer in a subject's biofluid by quantifying and comparing positive and negative fold changes in metabolite species' concentration; comparing the subject's metabolite species' concentrations to a predetermined value. | 02-26-2015 |
Vincent Moseti Asiago, Johnston, IA US
Patent application number | Description | Published |
---|---|---|
20130023056 | EARLY DETECTION OF RECURRENT BREAST CANCER USING METABOLITE PROFILING - A monitoring test for recurrent breast cancer with a high degree of sensitivity and specificity is provided that detects the presence of a panel of multiplicity of biomarkers that were identified using metabolite profiling methods. The test is capable of detecting breast cancer recurrence about a years earlier than current available monitoring diagnostic tests. The panel of biomarkers is identified using a combination of nuclear magnetic resonance (NMR) and two dimensional gas chromatography-mass spectrometry (GC×GC-MS) to produce the metabolite profiles of serum samples. The NMR and GC×GC-MS data are analyzed by multivariate statistical methods to compare identified metabolite signals between samples from patients with recurrence of breast cancer and those from patients having no evidence of disease. | 01-24-2013 |